 | |
| Clinical data | |
|---|---|
| Other names | CT-1812; CT1812; Elayta |
| Drug class | Sigmaσ2 receptorantagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H33NO4S |
| Molar mass | 431.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zervimesine (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name;[1] developmental code nameCT-1812 ORCT1812; tentative brand nameElayta) is asigmaσ2 receptorantagonist which is under development for the treatment ofAlzheimer's disease,dementia,dry age-related macular degeneration, and other indications.[2][3][4]
The sigma σ2 receptor is a binding site forβ-amyloidoligomers.[4] Zervimesine has been found to diplace β-amyloid oligomers from the sigma σ2 receptor in bothpreclinical andclinical studies.[4] As of 2024, effectiveness data on zerimesine for treatment of Alzheimer's disease are still lacking.[4]
Zervimesine is under development by Cognition Therapeutics.[2] As of July 2025, it is inphase 2clinical trials for Alzheimer's disease, dementia, and dry age-related macular degeneration and is inpreclinical research forParkinson's disease.[2] The drug was also being developed for treatment of othercognition disorders, but development for this indication was discontinued.[2]